Skip to content
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
  • Investors & Media
  • Contact Us
  • Investors & Media
  • Contact Us
Ironwood Pharmaceuticals Logo
Ironwood Pharmaceuticals
Close
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions

Category: Uncategorized

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference/default.aspx

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/FDA-Approves-Use-of-LINZESS-linaclotide-in-Pediatric-Patients-Two-Years-of-Age-and-Older-with-Functional-Constipation-FC/default.aspx

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Reports-Strong-First-Quarter-2026-Results-With-97-Year-Over-Year-LINZESS-U-S–Net-Sales-Growth-Maintains-Full-Year-2026-Financial-Guidance/default.aspx

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Survey-Findings-at-DDW-2026-Underscore-Need-for-Therapies-that-Address-Multiple-Dimensions-of-Total-Parenteral-Nutrition-TPN-Burden-in-Short-Bowel-Syndrome-SBS/default.aspx

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2026-Investor-Update-Call/default.aspx

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Share-Real-World-HCP-Perspectives-on-Burden-of-Total-Parenteral-Nutrition-in-Short-Bowel-Syndrome-SBS-at-Digestive-Disease-Week-2026/default.aspx

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspx

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Achieves-2025-Financial-Guidance-and-Reiterates-Strong-2026-Outlook/default.aspx

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2025-Investor-Update-Call/default.aspx

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Maintains-FY-2025-Financial-Guidance-and-Announces-FY-2026-Financial-Guidance/default.aspx

Next →
Ironwood Pharmaceuticals Home
  • Investors & Media
  • Contact Us
Linkedin Twitter
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Copyright © 2024 Ironwood. All rights reserved
  • Privacy Policy
  • Terms of Use
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
    • Investors & Media
    • Contact Us